Laird Norton Wetherby Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $400K | Buy |
+1,226
| New | +$400K | 0.02% | 640 |
|
|
2024
Q4 | $270K | Sell |
1,147
-204
| -15% | -$48K | 0.01% | 731 |
|
|
2024
Q3 | $372K | Buy |
1,351
+202
| +18% | +$55.6K | 0.02% | 658 |
|
|
2024
Q2 | $279K | Sell |
1,149
-297
| -21% | -$72.2K | 0.01% | 734 |
|
|
2024
Q1 | $216K | Sell |
1,446
-177
| -11% | -$26.5K | 0.01% | 855 |
|
|
2023
Q4 | $311K | Buy |
1,623
+326
| +25% | +$62.4K | 0.02% | 708 |
|
|
2023
Q3 | $230K | Sell |
1,297
-256
| -16% | -$45.3K | 0.01% | 772 |
|
|
2023
Q2 | $295K | Buy |
1,553
+191
| +14% | +$36.3K | 0.02% | 719 |
|
|
2023
Q1 | $273K | Sell |
1,362
-123
| -8% | -$24.6K | 0.02% | 738 |
|
|
2022
Q4 | $353K | Sell |
1,485
-202
| -12% | -$48K | 0.02% | 631 |
|
|
2022
Q3 | $338K | Buy |
+1,687
| New | +$338K | 0.02% | 614 |
|
|
2022
Q2 | – | Sell |
-1,313
| Closed | -$214K | – | 896 |
|
|
2022
Q1 | $214K | Buy |
1,313
+3
| +0.2% | +$489 | 0.01% | 834 |
|
|
2021
Q4 | $222K | Buy |
1,310
+48
| +4% | +$8.13K | 0.01% | 810 |
|
|
2021
Q3 | $238K | Buy |
1,262
+51
| +4% | +$9.62K | 0.01% | 777 |
|
|
2021
Q2 | $205K | Buy |
+1,211
| New | +$205K | 0.01% | 849 |
|